Clinical Trial Update: Camrelizumab Combined With Chemotherapy in First-line Treatment of HER2-positive Gastric Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating camrelizumab in combination with chemotherapy as first-line treatment for HER2-positive gastric cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• Camrelizumab (camrelizumab)

Snippet

Sponsor: Shengjing Hospital | Conditions: HER2-positive Gastric Cancer | Phase 2 | Status: UNKNOWN